Intellipharmaceutics Appoints New Chief Financial Officer

- September 1st, 2017

Intellipharmaceutics International announced the appointment of a new Chief Financial Officer.

Intellipharmaceutics (NASDAQ:IPCI; TSX:IPCI) announced the appointment of a new Chief Financial Officer.
As quoted in the press release:

Mr. Patient has more than 20 years’ experience with both Nasdaq- and TSX-listed companies, and has deep expertise in all facets of business, including operations, trade, finance, regulatory and business development, both nationally and internationally.   In December 2011, Mr. Patient became CFO at Merus Labs International Inc., a Nasdaq and TSX dual-listed specialty pharmaceutical company that owns, markets and distributes prescription medications. During a five-year period, Mr. Patient helped grow Merus from a one-drug domestic platform to a 12-drug, 36 country international platform. At Merus, Mr. Patient oversaw several significant acquisitions, and implemented a low-cost operating model with a light infrastructure footprint.  Mr. Patient was responsible for all accounting, finance and treasury functions, including external regulatory reporting, investor relations, and negotiating and executing key agreements for distribution and sales of products. Mr. Patient has been a Chartered Accountant (C.A.) since 1995.

Click here to read the full press release.


Leave a Reply